# Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma

> **NCT02701673** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Busulfan
- **DRUG:** Caphosol
- **DRUG:** Glutamine
- **DRUG:** Pyridoxine
- **DRUG:** Belinostat
- **DRUG:** Azacitidine
- **DRUG:** Gemcitabine
- **DRUG:** Melphalan
- **PROCEDURE:** Stem Cell Transplant

## Key facts

- **NCT ID:** NCT02701673
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-06
- **Primary completion:** 2019-06
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02701673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02701673, "Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02701673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*